Tumour suppressive mechanisms of CEBP? and PU.1 in acute myeloid leukemia [ 2014 - 2016 ]

Research Grant

Researchers: A/Pr Ross Dickins (Principal investigator) ,  Dr Matthew Ritchie

Brief description Acute myeloid leukaemia (AML) is an aggressive leukaemia with poor overall responses to therapy. The transcription factors CEBPA and PU.1 are often lost during AML development, and therapies that can restore their normal functions hold great promise. By identifying the genes that these transcription factors regulate in normal and leukaemic white blood cells, this project aims to understand how AML develops and which genes represent rational drug targets for this disease.

Funding Amount $AUD 497,827.46

Funding Scheme Project Grants

Notes Standard Project Grant